FOLH1 and epilepsy: In epilepsy models, inhibition of the NAAG degradation enzyme (glutamate carboxypeptidase II) and GRM3 agonists module seizure frequency [56], and activation of GRM3 in traumatic brain injury models indicates a protective effect.